JP2019502696A5 - - Google Patents

Download PDF

Info

Publication number
JP2019502696A5
JP2019502696A5 JP2018531529A JP2018531529A JP2019502696A5 JP 2019502696 A5 JP2019502696 A5 JP 2019502696A5 JP 2018531529 A JP2018531529 A JP 2018531529A JP 2018531529 A JP2018531529 A JP 2018531529A JP 2019502696 A5 JP2019502696 A5 JP 2019502696A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
compound according
disorder
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018531529A
Other languages
English (en)
Japanese (ja)
Other versions
JP7036725B2 (ja
JP2019502696A (ja
Filing date
Publication date
Priority claimed from GBGB1522179.9A external-priority patent/GB201522179D0/en
Application filed filed Critical
Publication of JP2019502696A publication Critical patent/JP2019502696A/ja
Publication of JP2019502696A5 publication Critical patent/JP2019502696A5/ja
Application granted granted Critical
Publication of JP7036725B2 publication Critical patent/JP7036725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018531529A 2015-12-16 2016-12-16 Ｋｖ３チャネルのヒダントインモジュレーター Expired - Fee Related JP7036725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522179.9 2015-12-16
GBGB1522179.9A GB201522179D0 (en) 2015-12-16 2015-12-16 Novel compounds
PCT/GB2016/053958 WO2017103604A1 (en) 2015-12-16 2016-12-16 Hydantoin modulators of kv3 channels

Publications (3)

Publication Number Publication Date
JP2019502696A JP2019502696A (ja) 2019-01-31
JP2019502696A5 true JP2019502696A5 (enExample) 2020-02-06
JP7036725B2 JP7036725B2 (ja) 2022-03-15

Family

ID=55274838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531529A Expired - Fee Related JP7036725B2 (ja) 2015-12-16 2016-12-16 Ｋｖ３チャネルのヒダントインモジュレーター

Country Status (7)

Country Link
US (1) US20200377485A1 (enExample)
EP (1) EP3390394B1 (enExample)
JP (1) JP7036725B2 (enExample)
CN (1) CN108430995A (enExample)
BR (1) BR112018012177A2 (enExample)
GB (1) GB201522179D0 (enExample)
WO (1) WO2017103604A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
HRP20241318T1 (hr) 2018-10-16 2024-12-20 Autifony Therapeutics Limited Novi spojevi
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
TW202031645A (zh) 2018-10-30 2020-09-01 丹麥商Ｈ 朗德貝克公司 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
US20220220095A1 (en) 2019-04-26 2022-07-14 H. Lundbeck A/S N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
WO2020216919A1 (en) 2019-04-26 2020-10-29 H. Lundbeck A/S ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kν3 POTASSIUM CHANNEL ACTIVATORS
PH12022551955A1 (en) * 2020-02-06 2023-10-23 Autifony Therapeutics Ltd Novel compound
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
IL310160A (en) 2021-08-10 2024-03-01 Autifony Therapeutics Ltd potassium channel modulators
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299383A (ja) * 1985-10-28 1987-05-08 Tokuyama Soda Co Ltd エ−テル化合物の製造方法
JP2005538155A (ja) * 2002-09-05 2005-12-15 メディヴィル・アクチボラグ 非ヌクレオシド逆転写酵素インヒビター
US20050080100A1 (en) * 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
EP1845087A1 (en) * 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
PT2563776T (pt) * 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
US9346790B2 (en) * 2010-12-06 2016-05-24 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20130030012A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Compounds
BR112014028718A2 (pt) * 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
JP6226967B2 (ja) * 2012-06-06 2017-11-08 ヴァンダービルト ケミカルズ、エルエルシー 燃費効率がよい潤滑油
CA2922567A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof

Similar Documents

Publication Publication Date Title
JP2019502696A5 (enExample)
JP2015517563A5 (enExample)
ES2660831T3 (es) Derivados de imidazol condensados útiles como inhibidores de IDO
RU2409576C2 (ru) Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
RU2487124C2 (ru) Новое амидное производное и его использование в качестве лекарственного средства
MX2021008358A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
JP2020502092A5 (enExample)
WO2012009258A3 (en) Peptidomimetic galanin receptor modulators
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
JP2016511258A5 (enExample)
JP2019509291A5 (enExample)
WO2017040993A4 (en) Small molecule inhibitors of dyrk1a and uses thereof
JP2016538313A5 (enExample)
JP2016040288A5 (enExample)
JP2017513894A5 (enExample)
JP2016525102A5 (enExample)
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
JP2014514290A5 (enExample)
JP2015500223A5 (enExample)
RU2015112914A (ru) Бензимидазолы в качестве активных агентов для центральной нервной системы
JP2020500866A5 (enExample)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2019506367A5 (enExample)
JP2019520344A5 (enExample)
MX2018001979A (es) (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.